Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zheng Qing Lingzhi Series is a line of traditional Chinese medicine (TCM) products developed and marketed by Hunan Zhengqing Pharmaceutical Group (also referred to as Hunan Zhongqi Pharmaceutical). These products are derived from *Ganoderma lucidum* (Lingzhi or Reishi mushroom), a fungus widely used in East Asian medicine for its immunomodulatory, anti-inflammatory, and antioxidant properties. The series includes various formulations such as capsules and oral liquids. These products are typically indicated for the treatment of neurasthenia, insomnia, loss of appetite (anorexia), and chronic bronchitis. They are also frequently utilized as adjuvant therapy to enhance immune function in patients with chronic diseases or those undergoing chemotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zheng Qing Lingzhi Series.